Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bionano GenomicsMEX:BNGO 61 9-Day RSI is 28.77 as of Jul. 26, 2026. GuruFocus rates MEX:BNGO with a GF Score™ of 61/100 and a GF Value™ of MXN26.17 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 865 Medical Devices & Instruments companies, Bionano Genomics ranks better than 68.67% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
As of today (2026-07-26), Bionano Genomics's 9-Day RSI is 28.77.
The industry rank for Bionano Genomics's 9-Day RSI or its related term are showing as below:
MEX:BNGO's 9-Day RSI is ranked better than 68.67% of 865
companies
in the Medical Devices & Instruments industry
Industry Median: 43.08
vs MEX:BNGO: 28.77
Bionano Genomics (MEX:BNGO) 9-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections. A shorter period RSI is more reactive to recent price changes, so it can show early signs of reversals. 9-Day RSI is sometimes used together with 14-Day RSI in a two period divergence strategy.
Bionano Genomics 9-Day RSI Related Terms
MEX:BNGO vs UEEC, CUPR, FEMY: 9-Day RSI Comparison
For the Medical Instruments & Supplies subindustry, Bionano Genomics's 9-Day RSI, along with its competitors' market caps and 9-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionano Genomics 9-Day RSI vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bionano Genomics's 9-Day RSI distribution charts can be found below:
* The bar in red indicates where Bionano Genomics's 9-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bionano Genomics (MEX:BNGO) has a 9-Day RSI of 28.77 as of Jul. 26, 2026. According to the industry distribution chart, Bionano Genomics ranks #271 out of 865 companies in the Medical Devices & Instruments industry, placing it in the top 31.3%.
Is Bionano Genomics' 9-Day RSI too high?
Bionano Genomics' current 9-Day RSI is 28.77. The Medical Devices & Instruments industry median 9-Day RSI is 43.08. Bionano Genomics' value of 28.77 is 33.2% below this industry median. Based on the distribution chart, Bionano Genomics ranks #271 out of 865 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Bionano Genomics has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bionano Genomics' 9-Day RSI compare to UEEC and CUPR?
According to the Medical Devices & Instruments industry distribution chart, Bionano Genomics ranks #271 out of 865 companies for 9-Day RSI. This puts Bionano Genomics in the upper half of its industry. The industry median 9-Day RSI is 43.08. Bionano Genomics' value of 28.77 is 33.2% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 9-Day RSI for a Medical Devices & Instruments company?
The median 9-Day RSI among Medical Devices & Instruments companies is 43.08, based on 865 companies in the industry. Companies in the top quartile (top 25%) have a 9-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 9-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bionano Genomics's current 9-Day RSI of 28.77 is 33.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 9-Day RSI mean?
A high 9-Day RSI can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median 9-Day RSI is 43.08 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionano Genomics's current 9-Day RSI is 28.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionano Genomics stock overvalued right now?
Based on GuruFocus' analysis, Bionano Genomics (MEX:BNGO) is currently considered Modestly Undervalued. The stock's GF Value™ is MXN26.17, compared to a current price of MXN20.00 — trading 23.6% below its estimated fair value. The current 9-Day RSI is 28.77 and 33.2% below the Medical Devices & Instruments industry median of 43.08. Bionano Genomics' overall GF Score™ is 61/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 9-Day RSI calculated?
9-Day RSI is calculated from a company's financial statements. For Bionano Genomics (MEX:BNGO), the current 9-Day RSI is 28.77 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bionano Genomics (MEX:BNGO) Overvalued in 2026?
Based on GuruFocus' analysis, Bionano Genomics stock appears to be undervalued.
The current stock price of MXN20.00 is trading 23.6% below its estimated GF Value™ of MXN26.17.
GuruFocus considers Bionano Genomics to be Modestly Undervalued.
Key valuation signals for MEX:BNGO:
9-Day RSI: 28.77
GF Value™: MXN26.17 vs. price of MXN20.00 (23.6% below fair value)
Industry Position: 33.2% below the Medical Devices & Instruments median (#271 of 865)
No single metric tells the full story. See the MEX:BNGO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes. Geographically, it operates in the Americas, EMEA, and Asia Pacific, of which the EMEA region generates the majority of its revenue. It generates product revenue from sales of its OGM and Ionic Purification systems and consumables, which include its instruments and their VIA software.
61GF Score
Get the complete analysis for MEX:BNGO
9-Day RSI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BNGO has been successfully added to your 
